FITC-heparin binding by live, apoptotic, and necrotic cells of different lineage and according to different treatment
| Cell line . | Treatment . | Live . | Apoptotic . | Necrotic . | |||
|---|---|---|---|---|---|---|---|
| RFI . | ± SEM . | RFI . | ± SEM . | RFI . | ± SEM . | ||
| Jurkat | no treatment | 2.6 | 0.0 | — | — | — | — |
| Camptothecin 11 μM/6 h | — | — | 6.3 | 0.6 | 510.0 | 101.0 | |
| 7-ketocholesterol 110 μM/6 h | — | — | 17.2 | 2.6 | 772.4 | 69.0 | |
| CD95 (Fas) antibody 5 μg/ml/6 h | — | — | 7.5 | 0.2 | 656.0 | 109.0 | |
| THP-1 | no treatment | 5.9 | 0.1 | — | — | — | — |
| Camptothecin 11 μM/6 h | — | — | 18.0 | 1.4 | 686.0 | 71.0 | |
| 7-ketocholesterol 110 μM/6 h | — | — | 67.0 | 1.8 | 564.0 | 65.0 | |
| HL-60 | no treatment | 6.7 | 0.1 | — | — | — | — |
| Camptothecin 11 μM/6 h | — | — | 70.0 | 7.1 | 448.0 | 51.0 | |
| 7-ketocholesterol 110 μM/6 h | — | — | 107.0 | 7.0 | 868.0 | 76.0 | |
| U937 | no treatment | 3.6 | 0.2 | — | — | — | — |
| Camptothecin 110 μM/6 h | — | — | 1.6 | 0.1 | 173.0 | 61.0 | |
| 7-ketocholesterol 110 μM/6 h | — | — | 16.8 | 3.0 | 235.0 | 17.0 | |
| Fresh leukocytes | no treatment | 2.2 | 0.2 | — | — | — | — |
| Camptothecin 11 μM/6 h | — | — | 17.2 | 0.5 | 92.0 | 3.8 | |
| Mean | 4.2 | 0.1 | 32.9 | 2.4 | 500.4 | 62.4 | |
| Cell line . | Treatment . | Live . | Apoptotic . | Necrotic . | |||
|---|---|---|---|---|---|---|---|
| RFI . | ± SEM . | RFI . | ± SEM . | RFI . | ± SEM . | ||
| Jurkat | no treatment | 2.6 | 0.0 | — | — | — | — |
| Camptothecin 11 μM/6 h | — | — | 6.3 | 0.6 | 510.0 | 101.0 | |
| 7-ketocholesterol 110 μM/6 h | — | — | 17.2 | 2.6 | 772.4 | 69.0 | |
| CD95 (Fas) antibody 5 μg/ml/6 h | — | — | 7.5 | 0.2 | 656.0 | 109.0 | |
| THP-1 | no treatment | 5.9 | 0.1 | — | — | — | — |
| Camptothecin 11 μM/6 h | — | — | 18.0 | 1.4 | 686.0 | 71.0 | |
| 7-ketocholesterol 110 μM/6 h | — | — | 67.0 | 1.8 | 564.0 | 65.0 | |
| HL-60 | no treatment | 6.7 | 0.1 | — | — | — | — |
| Camptothecin 11 μM/6 h | — | — | 70.0 | 7.1 | 448.0 | 51.0 | |
| 7-ketocholesterol 110 μM/6 h | — | — | 107.0 | 7.0 | 868.0 | 76.0 | |
| U937 | no treatment | 3.6 | 0.2 | — | — | — | — |
| Camptothecin 110 μM/6 h | — | — | 1.6 | 0.1 | 173.0 | 61.0 | |
| 7-ketocholesterol 110 μM/6 h | — | — | 16.8 | 3.0 | 235.0 | 17.0 | |
| Fresh leukocytes | no treatment | 2.2 | 0.2 | — | — | — | — |
| Camptothecin 11 μM/6 h | — | — | 17.2 | 0.5 | 92.0 | 3.8 | |
| Mean | 4.2 | 0.1 | 32.9 | 2.4 | 500.4 | 62.4 | |
Leukocyte cells were treated as shown, and the binding of FITC-heparin at 500 nM to live, apoptotic, and necrotic cells was determined as described in the legend to Figure 2. Results shown are the mean of values for RFI (see “Materials and methods”) observed in 3 experiments. Untreated cells are those to which vehicle alone was added.